Sanjay Murthy, The Ottawa Hospital (IMAGE)

The Ottawa Hospital

Sanjay Murthy, The Ottawa Hospital

Caption

The introduction of infliximab (Remicade), the first biologic therapy approved for the treatment of inflammatory bowel diseases (IBD), did not result in lower rates of hospitalizations or intestinal surgeries among patients living with IBD in Ontario, according to a study published by authors from several Canadian hospitals and ICES in the journal Gut.

Credit

The Ottawa Hospital

Usage Restrictions

This image may only be used in content related to this research study

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.